Inhibitors for many of the proteins in these signalling pathways have also been developed to treat different kinds of cancer and metabolic diseases, such as against sulfotransferases (Chapman et al, 2002; Rath et al, 2004), the cytochrome daf‐9/CYP2J2 (Chen et al, 2009), sulfatases (Mostafa & Taylor, 2013; Yue et al, 2016; Pérez‐Jiménez et al, 2021) and modulators of NHRs (Chen, 2008; Pinne & Raucy, 2014; Davis et al, 2018; Hong et al, 2018; Kang et al, 2018). This evidence concerns the gene CYP2J2 and metabolic disease.